Medical treatment Flashcards

1
Q

PDE5i
3 CI
6 medical conditions

A

Nitrates
Nicorandil
α1-blockers doxazosin and terazosin
unstable angina pectoris
recent myocardial infarction (< three months) or stroke (< six months)
myocardial insufficiency (New York Heart Association stage > 2)
hypotension
poorly controlled blood pressure
significant hepatic or renal insufficiency
anterior ischaemic optic neuropathy with sudden loss of vision is known or was reported after previous use of PDE5Is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

conservative watchful waiting treatment

A

Recommended for - Mild to moderate LUTS, low bother:
Education and reassurance
Reasonable fluid intake – avoidance/reduction in alcohol and caffeine intake
Earlier last drink of the day
Timed voiding (bladder re-training)
Double voiding, urethral milking
Distraction techniques
Monitor with flow rate and PMBS and FVC/IPSS
Address reversible factors for example, metabolic syndrome, co-morbidity, medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

% stable on watcful waiting

A

81% stable after f/u 17 months WW

Netto 1999

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

natural history of prostatism
Ball
1981

A
40% stable
25% got better
30% got worse
2% AUR
10% progress to surgical intervention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

efficacy of alpha blockers

A

reduce IPSS by 4 points in 30%
Djavan increase IPSS in 30-40%
increase flow rate 16-25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

tamulosin type

A

Alpha 1a selective
less hypotension than alfuzosin
retrograde ejaculation greater with tamsulosin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

tamulosin type

A

Alpha 1a selective
less hypotension than alfuzosin
retrograde ejaculation greater with tamsulosin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

retrograde ejaculation incidence tamsulosin

A

8.4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

side effects tamsulosin

A
asthenia
dizziness
postural hypotension
retograde ejaculation
rhinitis
floppy iris syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

% stop takin tam due to lack efficacy

A

30% stop taking due to lack of efficacy or side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5ARi reduction in symptom score

A

by 15% but not better placebo if prostate less than 40cc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

side effect 5ARI (4)

A

decreased libido
impotence
breast enlargement
rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ALFAUR

A
10mg od
age >50
no previous AUR
RV 500-1500mls
360 patients
ALF vs PLACEBO
2 x higher change successful TWOC with alfuzosin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

theoretical risk retention anti cholinergics if pvr and qmax

A

pvr more than 200mls

qmax less than 5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

nocturia desmopressin dosing licence

A
50mcg in men
25mcg in women
once daily
before sleeping
avoid fluid one hour before and 8 hours after

in over 65s can consider start low dose 10mcg and then increase to 50mcg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

action of desmopressin

A

AVP synthetic analogue for V2 receptor

avoids V1 receptor -hypertension

16
Q

side effects desmopressin 4

A

3 % hyponatraemia
1% hypertension
10% headache
3% nausea

17
Q

EAU recommendation for desmopressin

A
check sodium at baseline
day 3
day 7 
one month
stop if below range <135
inclusion some trials sodium above 130
18
Q

NICE desmopressin guidance

A

• The 50 μg dose of desmopressin (oral lyophilisate) is licenced for men with nocturia due to idiopathic nocturnal polyuria in all adults, including the over 65’s.

  • Serum sodium monitoring is recommended only in the over 65’s before initiating treatment, in the first week (4-8 days after initiation) and again at one month.
  • Treatment should be discontinued if the serum sodium falls below the lower range (<135)
  • Clinically significant (moderate to severe) hyponatraemia occurred in 2% of patients receiving low dose desmopressin in the phase III clinical trials
19
Q

forms of 5AR

A

two isoforms of the 5alpha reductase enzyme
type 1 minor expression in prostate mainly in skin and liver
type 2 in prostate
5ARI competative inhibition of enzme

20
Q

NNT of finasteride to prevent AUR

A

25

21
Q
after 2 -4 years of 5ARi treatment
improvement
IPSS
decrease prostate volume
increase flow rate
A

15-30%
volume <28%
qmax less than 2

22
Q

finasteride vs placebo for prostate less than 40mls

A

same as placebo

23
Q

how does finasteride reduce bleeding 3

A

micro vessel density
decrease VEGF expression
decrease prostatic blood flow